Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

aDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea bDivision of Hematology-Oncology, Department of ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...